Taro Sues Suven To Block Generic Lice Treatment

Law360, New York (May 3, 2011, 1:24 PM EDT) -- Taro Pharmaceuticals North America Inc. filed suit against Suven Life Sciences Ltd. in New Jersey federal court Thursday in an effort to keep it from producing a generic version of head lice treatment Ovide.

Taro claims that India-based Suven's abbreviated new drug application seeking approval from the U.S. Food and Drug Administration to sell its own malathion lotion infringes Taro's patent for the lice killer, which the company markets as Ovide.

The patent-in-suit, U.S. Patent Number 7,560,445, covers pharmaceutical grade malathion, a process for preparing highly...
To view the full article, register now.